|
Nov 5
|
3 Spectacular High-Yield Dividend Stocks to Buy in November
|
|
Nov 3
|
Alnylam (ALNY) Swings to Earnings in Q3 on Collaboration Revenues
|
|
Oct 27
|
Incyte (INCY) to Report Q3 Earnings: What's in the Cards?
|
|
Oct 27
|
Pharma Stock Roundup: SNY, MRK, NVS Report Q3 Earnings, FDA Okays PFE, LLY Products
|
|
Oct 27
|
2 Green Flags and 1 Red Flag for Novartis Stock
|
|
Oct 25
|
Novartis AG (NYSE:NVS) Q3 2023 Earnings Call Transcript
|
|
Oct 24
|
Novartis Hikes Its Earnings Outlook For The Third Time This Year
|
|
Oct 24
|
Novartis Ag (NVS) Q3 2023 Earnings Call Transcript
|
|
Oct 24
|
Novartis Expects $1 Billion in Revenue From This Cancer Drug This Year
|
|
Oct 24
|
Novartis (NVS) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates
|
|
Oct 24
|
Novartis (NVS) Tops Q3 Earnings, Ups Operating Income View
|
|
Oct 24
|
Novartis Begins New Era With Profit Beat and Guidance Hike. Investors Are Cautious.
|
|
Oct 24
|
Pharmaceutical industry close to deal with UK on drug pricing, says Novartis
|
|
Oct 24
|
Novartis Raises Earnings Guidance After Key Drugs Boost Profit, Sales
|
|
Oct 24
|
Novartis lifts 2023 earnings forecast for third time
|
|
Oct 24
|
Novartis delivers 12% sales and 21% core operating income growth from continuing operations (in cc¹). Executes Sandoz spin-off, achieves important innovation milestones, and raises FY 2023 guidance
|
|
Oct 23
|
Novartis Pluvicto™ shows clinically meaningful and highly statistically significant rPFS benefit in patients with PSMA-positive metastatic castration-resistant prostate cancer in the pre-taxane setting
|
|
Oct 20
|
Novartis (NVS) to Report Q3 Earnings: What's in the Offing?
|
|
Oct 20
|
Novartis Kisqali® NATALEE analysis reinforces consistent reduction in risk of recurrence across key subgroups of patients with early breast cancer
|
|
Oct 18
|
Novartis (NVS) Stock Moves -0.4%: What You Should Know
|